Express Mail Label No: EV669116526 US
Date of Deposit: March 17, 2005

IN THE UNITED STATES OF TENT AND TRADEMARK OFFICE

APPLICANTS:

Saragovi, et al.

SERIAL NUMBER:

10/600,623

FILING DATE:

June 20, 2003

For:

COMPOUND TARGETED FOR SPECIFIC CELLS WITH

REDUCED SYSTEMIC TOXICITY

GROUP ART UNIT:

1642

EXAMINER:

Brandon J. Fetterolf

March 17, 2005

Boston, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This paper is in response to the Restriction Requirement dated November 17, 2004 for the above-referenced patent application.

Applicants hereby elect Group III, claim 30, as specifically drawn to a method for by-passing resistance of tumor cells by p-glycoprotein pump (PGP), classified in class 424, subclass 178.1 without traverse.

The Examiner further requests that the Applicants choose one "therapeutic" agent from those listed in claim 1 or 5. Applicants respectfully choose the chemotherapeutic agent as the therapeutic agent.

Applicants reserve the right to prosecute the non-elected claims in subsequent continuation and/or divisional applications.

Applicants further request a petition for a three-month (3) extension of time under 37 C.F.R. 1.17(a)(3). With the extension the Response to the Restriction Requirement is timely due on or before March 17, 2005. The Commissioner is hereby authorized to charge the petition fee (\$510.00), to Deposit Account No. 50-3431, Attorney Reference No. OGIL-002 US), formerly 62950-010310. A duplicate copy of this Response is enclosed. Applicant is a small entity.

Respectfully submitted,

James F. Ewing, Reg. No. 52/,875

Attorney for Applicants Customer No.: 48329

Foley & Lardner LLP
111 Huntington Avenue

Boston, Massachusetts 02199

Tel: (617) 342-4000 Fax: (617) 342-4001

#153562 v1